APLM Apollomics, Inc.
USHealthcareAs of 2026-07-09 09:34
Why APLM matters now
Apollomics, Inc. (APLM) is a US stock in Healthcare. The latest InvestLog snapshot shows $19.50 with +2.04% on the session and $21.5M in market capitalization; recent performance reads 1-month +23.23% and YTD -6.43%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $1.6M, and EPS of $3.80. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -66.1%.
The latest indexable market news headline is "Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes LIN PETER KUAN-HOW filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.31
P/S
2.27
EV/EBITDA
-1.76
DCF Value
$-580.16
FCF Yield
-66.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-111.4%
Net Margin
-128.7%
ROE
288.4%
ROA
-162.9%
ROIC
-1586.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $1.6M | $3.80 |
| FY 2025 | $8.5M | $-10.9M | $-7.57 |
| Q2 2025 | $8.5M | $-12.5M | $-11.37 |
| Q4 2024 | $-1.6M | $-18.7M | $-16.92 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.53
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.